These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

102 related items for PubMed ID: 2474522

  • 21. Changes in prostate-specific markers under chronic gonadotrophin-releasing hormone analogue treatment of state D prostatic cancer.
    Matzkin H, Lewyshon O, Ayalon D, Braf Z.
    Cancer; 1989 Apr 01; 63(7):1287-91. PubMed ID: 2465816
    [Abstract] [Full Text] [Related]

  • 22. Gn-RH agonists in the treatment of prostatic carcinoma.
    Vacher P.
    Biomed Pharmacother; 1995 Apr 01; 49(7-8):325-31. PubMed ID: 8562857
    [Abstract] [Full Text] [Related]

  • 23. [Endocrine therapy for prostatic carcinoma--the clinical trial to compare the efficacy of LH-RH analogue, ICI 118630 (Zoladex) with castration or estrogen].
    Usami M, Kotake T, Matsuda M, Okajima E, Osafune M, Akaza H, Niijima T, Aso Y, Araki T, Itatani H.
    Hinyokika Kiyo; 1988 Oct 01; 34(10):1853-63. PubMed ID: 2977527
    [Abstract] [Full Text] [Related]

  • 24. The value of prostate-specific antigen in the management of localized prostatic cancer.
    Walsh PC, Oesterling JE, Epstein JI, Bruzek DJ, Rock RC, Chan DW.
    Prog Clin Biol Res; 1989 Oct 01; 303():27-33. PubMed ID: 2476820
    [Abstract] [Full Text] [Related]

  • 25. The value of prostatic acid phosphatase and prostate specific antigen as serum markers in carcinoma of the prostate.
    Akdaş A, Simşek F, Ilker Y, Türkeri L, Ercan H.
    Int Urol Nephrol; 1993 Oct 01; 25(3):271-8. PubMed ID: 7693607
    [Abstract] [Full Text] [Related]

  • 26. [The significance of serum prostate-specific antigen, gamma-seminoprotein and prostatic acid phosphatase as prostate cancer markers].
    Yamaguchi K, Tanaka M, Kitagawa N, Kotake T, Yanagi S, Ito H.
    Hinyokika Kiyo; 1989 Jun 01; 35(6):987-91. PubMed ID: 2478006
    [Abstract] [Full Text] [Related]

  • 27. PSA evolution: a prognostic factor during treatment of advanced prostatic carcinoma with total androgen blockade. Data from a Belgian multicentric study of 546 patients.
    Oosterlinck W, Mattelaer J, Casselman J, Van Velthoven R, Derde MP, Kaufman L.
    Acta Urol Belg; 1997 Oct 01; 65(3):63-71. PubMed ID: 9421938
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Long-term effectiveness of luteinizing hormone-releasing hormone agonist or antiandrogen monotherapy in elderly men with localized prostate cancer (T1-2): a retrospective study.
    Raina R, Pahalajani G, Agarwal A, Zippe C.
    Asian J Androl; 2007 Mar 01; 9(2):253-8. PubMed ID: 17334592
    [Abstract] [Full Text] [Related]

  • 35. Immunologic markers and the diagnosis of prostatic cancer.
    Ban Y, Wang MC, Chu TM.
    Urol Clin North Am; 1984 May 01; 11(2):269-76. PubMed ID: 6203206
    [Abstract] [Full Text] [Related]

  • 36. [The clinical and prognostic value of inversion of the PSA/PAP ratio in prostatic cancer].
    Morote Robles J, Lorente JA, Reig C, López Pacios MA, de Torres JA, Soler Roselló A.
    Actas Urol Esp; 1994 May 01; 18(5):559-61. PubMed ID: 7521563
    [Abstract] [Full Text] [Related]

  • 37. Economics of screening for carcinoma of the prostate.
    Optenberg SA, Thompson IM.
    Urol Clin North Am; 1990 Nov 01; 17(4):719-37. PubMed ID: 1699340
    [Abstract] [Full Text] [Related]

  • 38. Clinical importance of prostatic measurements in follow-up of GnRH analogue-treated prostatic carcinoma patients.
    Matzkin H, Greenstein A, Braf Z.
    Urology; 1990 Sep 01; 36(3):214-8. PubMed ID: 2118285
    [Abstract] [Full Text] [Related]

  • 39. [Treatment of advanced prostatic carcinoma with a depot LH-RH analog (ICI 118630)].
    Grifoni R, Pierangeli T.
    Minerva Urol Nefrol; 1989 Sep 01; 41(1):5-10. PubMed ID: 2527415
    [Abstract] [Full Text] [Related]

  • 40. [The value of prostate-specific antigen].
    Wirth M.
    Urologe A; 1991 May 01; 30(3 Suppl):6. PubMed ID: 1720907
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.